Investigational Therapeutics That Restore Brain Synapses
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
A New Approach to the Brain’s Lost Connections
Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X Syndrome (FXS) and many others.
Latest Press Releases
New Peer-Reviewed Research Demonstrates Neurophysiological Efficacy of Spinogenix’s SPG601 in Patients with Fragile X Syndrome
April 9, 2026
Study Results, Published in Nature Scientific Reports, Found SPG601 Reduced Signature Changes in High-Frequency Gamma Band Activity and Improved Cognition in FXS Patients LOS ANGELES, April 9, 2026 —...
Spinogenix Reports Early Improvements in Phase 2 Trial of Tazbentetol in Patients with Schizophrenia at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress
March 26, 2026
First-in-Class Synaptic Regenerative Therapy Demonstrates Favorable Safety Profile and Early Potential to Improve Symptoms of Schizophrenia LOS ANGELES, March 26, 2026 /PRNewswire/ — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics...
Spinogenix Completes Enrollment in Phase 2 Clinical Trial of Tazbentetol for Schizophrenia Treatment
March 11, 2026
First-in-Class Synaptic Regenerative Therapy Aims to Address Positive, Negative and Cognitive Symptom Domains Oral Presentation on Interim Data Planned for Schizophrenia International Research Society (SIRS) Annual Congress LOS ANGELES...
In the News
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
December 9, 2025
Topline data from a completed phase 2a trial (NCT05882695) highlighted the therapeutic benefits of SPG302, a synaptic regenerative drug, to treat patients with amyotrophic lateral sclerosis (ALS). All told, treatment...
From the Blog
Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
December 1, 2025
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our...